Karyopharm Therapeutics Inc.
NASDAQ:KPTIBiotechnology
-$0.34 today
- Market cap
- $158.87M
- Beta
- 0.82
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$8.86
Volume 0.67M
Average 0.85M
Returns on capital
Karyopharm Therapeutics Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
66.9%
avg 22.5%
ROIC
-236.6%
avg -86.8%
ROA
-180.8%
avg -67.6%
Analysis
ROE is currently the strongest return metric at 66.9% versus its period average of 22.5%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Reshma Rangwala | Executive Vice President, Chief Medical Officer & Head of Research | USD 1.82M | 48 | 56.83K | 0.25% |
Sharon Shacham | Co-Founder & Chairman of Scientific Advisory Board | USD 1.4M | 56 | 90.00K | 0.40% |
Richard A. Paulson | President, Chief Executive Officer & Director | USD 1.24M | 59 | 269.75K | 1.19% |
Stuart Poulton | Executive Vice President & Chief Development Officer | USD 971.55K | 53 | 94.82K | 0.42% |
Lori A. Macomber | Executive Vice President, Chief Financial Officer & Treasurer | USD 712.68K | 55 | — | — |
Michael J. Mano | Executive VP, Chief Legal Officer & Secretary | USD 625.08K | 49 | — | — |
Brendan Twohig Strong | Senior Vice President of Investor Relations | — | — | — | — |
Brian Austad | Senior Vice President of Pharmaceutical Sciences | — | — | — | — |
James Accumanno | Chief Compliance Officer | — | — | — | — |
Kristin Abate | Vice President, Chief Accounting Officer & Assistant Treasurer | — | — | 23.80K | 0.11% |
Lisa DiPaolo | Executive Vice President & Chief Human Resource Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Jul 25, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding May 14, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
16
$342,668.85
Net Transaction Value
−$342,668.85
Net selling
Most Active
Poulton Stuart
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| May 14, 26May 14, 2026 | Mano Michael Direct | Sell | $2.5K$2,527.00 |
| May 14, 26May 14, 2026 | Poulton Stuart Direct | Sell | $3.8K$3,828.50 |
| May 14, 26May 14, 2026 | Rangwala Reshma Direct | Sell | $3.9K$3,876.00 |
| May 14, 26May 14, 2026 | Cheng Sohanya Roshan Direct | Sell | $3.1K$3,078.00 |
| May 14, 26May 14, 2026 | Abate Kristin Direct | Sell | $503.5$503.50 |
| May 14, 26May 14, 2026 | Paulson Richard A. Direct | Sell | $20.9K$20,928.50 |
| Apr 21, 26Apr 21, 2026 | Rangwala Reshma Direct | Sell | $4K$4,014.06 |
| Mar 2, 26Mar 2, 2026 | Poulton Stuart Direct | Sell | $48K$47,997.86 |
| Mar 2, 26Mar 2, 2026 | Mano Michael Direct | Sell | $33.2K$33,177.90 |
| Mar 2, 26Mar 2, 2026 | Cheng Sohanya Roshan Direct | Sell | $43.3K$43,321.34 |
1–10 of 16
Summary
Insiders reported 0 buys worth $0.00 and 16 sells worth $342,668.85 over the last 12 months. That adds up to net selling of $342,668.85. Poulton Stuart was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -2.4% | +33.2% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at -2.4% over three years. Forward estimates point to Revenue at +33.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Karyopharm Therapeutics Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about KPTI's management, answered from reported figures.
Who manages KPTI?
Karyopharm Therapeutics Inc. (KPTI) lists 11 active executives. The top listed executive is Reshma Rangwala, Executive Vice President, Chief Medical Officer & Head of Research.
Are KPTI insiders buying or selling?
Recent insider activity shows net buying of $79,308.15.
Continue the stock analysis
Jump to another research area for this company.